FOXO4-DRI
FOXO4-DRI is a lab-made peptide studied as a senolytic, meaning it is meant to clear out senescent cells: old, damaged cells that stop dividing but do not die and leak inflammatory signals. All the evidence so far comes from mice and cell cultures.
At a glance
- Peptide
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- 250 mcg per Peptide Dosing Protocols. See the source
- 10 mg in 3 mL
How much to draw
Full calculator →Opened on 250 mcg, the figure Peptide Dosing Protocols reports for FOXO4-DRI, and a 10 mg vial in 3 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for FOXO4-DRI or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 250 mcg daily · Low: 250 mcg daily · High: 500 mcg daily | daily16 weeks · 4 weeks on, 4 weeks off | SubQ | Peptide Dosing ProtocolsWhat it saysHideStandard dosing starts at 250 mcg daily and increases to 500 mcg daily. |
- daily16 weeks · 4 weeks on, 4 weeks off
- SubQ
- Peptide Dosing Protocols
What it saysHide
Standard dosing starts at 250 mcg daily and increases to 500 mcg daily.
- 3.0 mL BAC water
We have not published an audit on FOXO4-DRI. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
The peptide is designed to break up a protein pairing inside senescent cells so the cell's own self-destruct machinery is freed to kill them. Researchers describe this as disrupting the FOXO4-p53 interaction so p53 can trigger apoptosis, the cell's programmed death; the D-retro-inverso build, mirror-image amino acids in reverse order, makes the peptide much harder for the body to break down. In mice, effects appeared within roughly 10-14 days, and the 2017 Baar et al. study in Cell reported restored coat density, better kidney markers and more physical activity in aged and chemotherapy-treated mice. As of June 2026 there is no completed or registered human trial, so human timing is unknown.
Disrupts the FOXO4-p53 interaction so p53 can trigger apoptosis in senescent cells. [Source: Peptide Dosing Protocols]
Reported side effects
Not ruled out: no human side effects have been documented, because FOXO4-DRI has never been tested in people, and the reference states that safety in mice does not predict safety in people. The concerns it lists are off-target killing of healthy cells that briefly carry high FOXO4; the strain of clearing a wave of dying cells; worse wound healing, since senescent cells help wounds repair; and redness, swelling or irritation where it is injected. Product quality is a separate risk, because the peptide is costly to synthesise and a single wrong amino acid at the binding site can sharply cut activity.
Who should avoid it
Anyone looking for a validated human treatment: FOXO4-DRI has never been tested in a human trial, and every figure comes from animal research or community self-reports.
People who need wound healing to work normally: senescent cells help wounds repair, so clearing them at the wrong time may not be wanted.
People relying on senescent cells for tumor suppression: those cells play a role in holding tumors in check, so clearing them indiscriminately carries a theoretical risk.
Anyone using unverified material: as a D-amino acid peptide it is expensive to make, and unverified product may not contain what the label claims.
What gets monitored
Useful markers for senescence biology include hs-CRP, IL-6, and IGF-1, alongside a comprehensive metabolic panel. (reported by Peptide Dosing Protocols)
Common questions
What is FOXO4-DRI?
FOXO4-DRI is a synthetic D-retro-inverso peptide studied as a senolytic, built to clear senescent cells selectively. Some vendors sell it under the name Proxofim.
What is FOXO4-DRI used for in research?
It is investigated mainly in cellular senescence and aging research. That work is in cells and animals, not people.
What dosing has been published for FOXO4-DRI?
The only published dosing comes from mouse studies, at 5 mg/kg by intraperitoneal injection, given about three times a week in the original work. Animal doses by body weight do not convert into a human dose.
How is a 10 mg FOXO4-DRI vial reconstituted?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Is there a FOXO4-DRI dosage chart?
The source guide includes a community-derived 16-week daily ladder. It states that this community schedule has no safety data behind it, and that subcutaneous community use was never tested in humans for uptake, safety or effect.
What are the side effects of FOXO4-DRI?
No human side effects have been documented, because it has not been tested in people. The listed concerns are theoretical ones such as off-target cell death and impaired wound healing, plus ordinary injection-site reactions.
Are there any FOXO4-DRI human trials?
No. As of June 2026 there are no completed or registered human clinical trials.
Is FOXO4-DRI FDA approved?
No. FOXO4-DRI is not FDA approved and has no approved human indication.
Sources
- 01Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell (2017)
- 02Madl T, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications (2025)
- 03Zhang C, Xie Y, Chen H, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY) (2020)
- 04Huang Y, He Y, Makarcyzk MJ, Lin H. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Frontiers in Cell and Developmental Biology (PMC8116695) (2021)
- 05Zhang H, et al. FOXO4-DRI regulates endothelial cell senescence via the p53 signaling pathway. PMC12852416 (2025)
- 06Yang Y, et al. FOXO4-DRI improves spermatogenesis in aged mice through reducing SASP secretion from Leydig cells. Mechanisms of Ageing and Development (2024)
- 07American Association for Cancer Research (Research Watch). A FOXO4 Inhibitory Peptide Limits Chemotoxicity in Mice. Cancer Discovery (2017)
- 08Le HH, et al. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine (2021)
- 09National Center for Biotechnology Information. FOXO4-DRI (PubChem CID 167312269) — compound identity and molecular formula. PubChem (2026)
- 10U.S. National Library of Medicine. ClinicalTrials.gov registry — FOXO4-DRI search (no registered human trials as of June 2026). ClinicalTrials.gov (2026)
- 11Lifespan.io Rejuvenation Roadmap. Cleara Biotech — FOXO4-DRI development status. Lifespan.io (industry/development context) (2026)
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.